FY2025 EPS Forecast for Journey Medical Decreased by Analyst
HC Wainwright has decreased its FY2025 EPS forecast for Journey Medical to ($0.53) from ($0.45), maintaining a "Buy" rating with a $13.00 target price. The stock has mixed ratings from analysts, with a consensus "Hold" rating and an average target price of $12.17. Journey Medical's recent quarterly earnings missed estimates, and the stock opened at $7.89 on NASDAQ. Institutional investors have been adjusting their positions in the company.
Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 EPS estimates for shares of Journey Medical in a report released on Thursday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.53) per share for the year, down from their previous estimate of ($0.45). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical's Q4 2025 earnings at ($0.10) EPS.
Several other brokerages have also weighed in on DERM. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Journey Medical in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Journey Medical from a "strong sell" rating to a "hold" rating in a report on Monday, October 13th. Finally, Lake Street Capital upped their price target on Journey Medical from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $12.17.
Get Journey Medical alerts:
View Our Latest Stock Analysis on Journey Medical
Journey Medical Stock Performance
NASDAQ DERM opened at $7.89 on Monday. The stock has a fifty day simple moving average of $7.65 and a 200-day simple moving average of $7.32. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75. The stock has a market cap of $207.59 million, a PE ratio of -22.54 and a beta of 0.80. Journey Medical has a twelve month low of $3.54 and a twelve month high of $9.40.
Journey Medical (NASDAQ:DERM - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Journey Medical had a negative return on equity of 39.94% and a negative net margin of 14.58%.The business had revenue of $17.63 million during the quarter, compared to analysts' expectations of $18.85 million.
Institutional Trading of Journey Medical
A number of large investors have recently made changes to their positions in DERM. Wasatch Advisors LP raised its holdings in Journey Medical by 23.8% in the second quarter. Wasatch Advisors LP now owns 1,152,059 shares of the company's stock valued at $8,272,000 after acquiring an additional 221,456 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Journey Medical by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 262,353 shares of the company's stock valued at $1,884,000 after purchasing an additional 148,612 shares in the last quarter. Sheets Smith Investment Management purchased a new stake in shares of Journey Medical during the 3rd quarter worth $946,000. Essex Investment Management Co. LLC lifted its position in shares of Journey Medical by 55.1% during the 3rd quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company's stock worth $2,521,000 after purchasing an additional 125,818 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Journey Medical by 8.9% during the third quarter. Vanguard Group Inc. now owns 615,229 shares of the company's stock worth $4,380,000 after purchasing an additional 50,241 shares in the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.
About Journey Medical
(Get Free Report)Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
See Also
- Five stocks we like better than Journey Medical
- Using the MarketBeat Dividend Yield Calculator
- 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
- What is Insider Trading? What You Can Learn from Insider Trading
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- What Investors Need to Know About Upcoming IPOs
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Journey Medical Right Now?
Before you consider Journey Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.
While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
